A strategic buyer makes an offer when its team can answer six questions. Here they are, and when to start the conversation.
Every Offer Starts With Six Answers
I spent years on the other side of this table, as a finance leader inside a large medical device company that bought other companies. Founders would come in with a strong product and a clean pitch, and our team would spend the meeting on questions they hadn’t prepared for. A strategic buyer doesn’t write an offer because it likes your business. It writes one when its operating team and its corporate development team can answer six questions well enough to defend the price to their own board.
Most owners don’t learn those questions until they’re in diligence. Here they are, followed by what I’d tell you about when to start the conversation. The examples come from medical devices because that’s where I sat, but the questions hold in any industry where a larger company buys a smaller one.
The Six Questions a Buyer’s Team Has to Answer
1. Does it fill a gap they have already mapped?
Strategic buyers know where their portfolio is thin. The question isn’t whether your product is good. It’s whether it fills a gap they already know they have, and whether you can say why this buyer needs it rather than why the science is impressive.
A pitch built around your product answers the wrong question. A pitch built around their gap answers the one they’re asking.
2. What can they do with it that you can’t?
This is what a strategic premium pays for. Their installed base, product portfolio, sales channel and customer relationships let them do more with your business than you can alone.
If you can show them that math, you’ve given them a reason to pay more than a financial buyer would. If you can’t, they’ll price you like everyone else.
3. How much risk is left, and can they model it?
Their team has to put a number on the risk they’d be taking on. In medical devices that means clinical and regulatory evidence, usually reproducible multi-site data, strong enough for their regulatory team to model the approval risk, cost and timeline still ahead. In other industries it’s whatever still stands between the product and scaled revenue.
Risk they can model gets priced. Risk they can’t model stalls the deal.
4. Do the numbers support the story they’ll tell their board?
Their board has to see a deal that adds to earnings, or has a credible path to it. They’ll look at your margins, growth and unit economics, and in healthcare, whether there’s a credible route to reimbursement.
The numbers don’t have to be large. They have to be believable, and they have to hold up when someone who didn’t build them starts asking questions.
5. Can their organization carry it?
Your product working in your hands is the easy part. The real test is whether their sales organization, quality systems, manufacturing and service teams can carry it at their scale.
A product that still depends on your founding team to sell or support it is a harder integration, and they’ll price that in.
6. Is it clean enough to close?
IP, freedom to operate, quality systems, supply chain and the cap table all get checked. A mess in any one of them slows the deal, reprices it, or kills it in diligence.
Most of these are manageable a year out. All of them are hard to fix with a buyer waiting.
When to Start the Conversation
Owners tend to approach strategics either too late, when they need the deal, or too early for the wrong reason. The timing matters less than what the first conversation is for.
Start early, but not to sell
The first conversation should test strategic fit and find out what the business unit would need to see before it would consider a deal. It isn’t a pitch for a transaction.
Owners who treat it as research learn what to build. Owners who treat it as a sales call usually get a polite no and learn nothing.
Stage the relationship
Strategic acquisitions rarely start as acquisitions. In medical devices the path usually runs from a technical evaluation to a pilot or clinical collaboration, then a minority investment, then distribution or co-promotion, and then a potential acquisition. Each step de-risks the next one for both sides.
In other industries the steps look different, such as a supply agreement or a shared customer, but the logic is the same.
Find the operating champion
The person who matters most sits inside the business unit that would own your product. Corporate venture participation without business-unit ownership rarely produces a transaction.
If a strategic keeps declining to invest or run a pilot after you’ve done the real de-risking work, that’s an answer, not a timing problem.
Protect your position
Build relationships with several strategics, not one. Be careful with broad rights of first refusal, exclusivity and information rights, especially early, when they can feel like the price of a partner’s attention.
Competitive tension is what protects your valuation when the offer comes, and those terms can take it away before you notice.
Where We Come In
Our operators have sat on both sides of the table, and as a team have taken more than 50 transactions to close. We embed as the finance and operating leaders who get a business ready to answer those six questions. That means building numbers a buyer’s team will trust, fixing what diligence would find, and being in the room when the questions come.
The Bottom Line
A strategic buyer has to answer six questions before it makes an offer. The owners who get the best price answered them first, and started the relationship long before they needed the deal.
If a strategic buyer is anywhere on your horizon, the time to start is before they call. We’ve sat in your seat. Now we’re in your corner.
Frequently Asked Questions
What is a strategic buyer?
A company that buys another business to add to its own operations, usually a larger player in the same or a neighboring market. A financial buyer, such as a private equity firm, is mainly paying for the business’s own earnings. A strategic is paying for what the business can do inside its own portfolio, which is why it can sometimes pay more.
Why would a strategic buyer pay more than a financial buyer?
Because it can do more with the business. Its customers, channel and product line can grow your product faster than you can alone, and part of that value can show up in the price as a strategic premium.
When should I first talk to a strategic acquirer?
Earlier than you think, and not to sell. The first conversation should test fit and find out what the business unit would need to see. Most strategic acquisitions come out of a staged relationship, so the clock starts well before a deal.
What slows down or kills a deal with a strategic buyer?
Problems with IP, freedom to operate, quality systems, supply chain or the cap table. Any one of them can slow a deal, reprice it or end it in diligence. They’re far easier to fix a year before a process than during one.
Should I agree to a right of first refusal with a strategic partner?
Be careful. A broad right of first refusal, exclusivity or wide information rights can keep other buyers away and take the competitive tension out of a sale, and that tension is what protects your valuation. Talk to your attorney before you sign one.
